The DOI matches its Crossref record; 261 of the 261 references it cites were found in a registry or an index.
Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy
Abstract
Most solid tumor cells adapt to their heterogeneous microenvironment by depending largely on aerobic glycolysis for energy production, a phenomenon called the Warburg effect, which is a hallmark of cancer. The altered energy metabolism not only provides cancer cell with ATP for cellular energy, but also generate essential metabolic intermediates that play a pivotal role in the biosynthesis of macromolecules, to support cell proliferation, invasiveness, and chemoresistance. The cellular metabolic reprogramming in cancer is regulated by several oncogenic proteins and tumor suppressors such as hypoxia-inducible factor (HIF-1), Myc, p53, and PI3K/Akt/mTOR pathway. A better understanding of the mechanisms involved in the regulation of aerobic glycolysis can help in developing glycolytic inhibitors as anticancer agents. These metabolic antiglycolytic agents could be more effective if used in drug combinations to combat cancer. Several preclinical and early clinical studies have shown the effectiveness of targeting the glycolytic pathway as a therapeutic approach to suppress cancer progression. This review aimed to present the most recent data on the emerging drug candidate targeting enzymes and intermediates involved in glucose metabolism to provide therapeutic opportunities and challenges for antiglycolytic cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–261 of 261
Lin, S.-T., Tu, S., Yang, P., Hsu, S., Lee, W., Ho, C., Wu, C., Lai, Y.-H., Chen, M., & Chen, L.-C. (2016) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.6b02861 · Cited by 96
Kaipparettu, B. A., Ma, Y., Park, J. H., Lee, T., Zhang, Y., Yotnda, P., Creighton, C. J., Chan, W., & Wong, L. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061747 · Cited by 95
Ganapathy‐Kanniappan, S., Kunjithapatham, R., & Geschwind, J.-F. H. (2012) · Oncotarget · doi:10.18632/oncotarget.623 · Cited by 94
Evidence from transgenic mice that myc regulates hepatic glycolysis
Valera, A., Pujol, A., Gregori, X., Riu, E., Visa, J., & Bosch, F. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.11.7649406 · Cited by 86
Nath, K., NELSON, D. S., Heitjan, D. F., Leeper, D. B., Zhou, R., & Glickson, J. D. (2014) · NMR in Biomedicine · doi:10.1002/nbm.3240 · Cited by 85
Berruti, A., Bitossi, R., Gorzegno, G., Bottini, A., Alquati, P., Matteis, A. D., Nuzzo, F., Giardina, G., Danese, S., Lena, M. D., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.012 · Cited by 84
Li, W., Hao, J., Zhang, L., Cheng, Z., Deng, X., & Shu, G. (2017) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.7b02120 · Cited by 84
Autophagy, Warburg, and Warburg Reverse Effects in Human Cancer
González, C. D., Álvarez, S., Ropolo, A., Rosenzvit, C., Bagnes, M. F. G., & Vaccaro, M. I. (2014) · BioMed Research International · doi:10.1155/2014/926729 · Cited by 82
mTOR signaling in osteosarcoma: Oncogenesis and therapeutic aspects (Review)
Hu, K., Dai, H.-B., & Qiu, Z.-L. (2016) · Oncology Reports · doi:10.3892/or.2016.4922 · Cited by 82
Spoden, G. A., Mazurek, S., Morandell, D., Bacher, N., Ausserlechner, M. J., Jansen‐Dürr, P., EIGENBRODT, E., & Zwerschke, W. (2008) · International Journal of Cancer · doi:10.1002/ijc.23512 · Cited by 80
Liu, J., Wu, N., Ma, L., Liu, M., Liu, G., Zhang, Y., & Lin, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091606 · Cited by 77
Sayed, S. M. E., Mohamed, W. G., Seddik, M.-A. H., Ahmed, A.-S. A., Mahmoud, A. G., Amer, W. H., Nabo, M. M. H., Hamed, A., Ahmed, N. S., & Abd-Allah, A. A.-R. (2014) · 癌症:英文版 · doi:10.5732/cjc.013.10111 · Cited by 77
Anticancer efficacy of the metabolic blocker 3-bromopyruvate: specific molecular targeting.
Ganapathy‐Kanniappan, S., Kunjithapatham, R., & Geschwind, J.-F. H. (2013) · PubMed · Cited by 76
Expression of SGLT1, Bcl-2 and p53 in Primary Pancreatic Cancer Related to Survival
Casneuf, V. F., Fonteyne, P., Damme, N. V., Demetter, P., Pauwels, P., de Hemptinne, B., Vos, M. D., de Wiele, C. V., & Peeters, M. (2008) · Cancer Investigation · doi:10.1080/07357900801956363 · Cited by 75
Balancing biosynthesis and bioenergetics: metabolic programs in oncogenesis
Barger, J. F., & Plas, D. R. (2010) · Endocrine Related Cancer · doi:10.1677/erc-10-0106 · Cited by 75
Wintzell, M., Löfstedt, L., Johansson, J., Pedersen, A. B., Fuxe, J., & Shoshan, M. C. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.22007 · Cited by 74
Vella, S., Conti, M., Tasso, R., Cancedda, R., & Pagano, A. (2011) · International Journal of Cancer · doi:10.1002/ijc.26173 · Cited by 73
Fanciulli, M., Bruno, T., Giovannelli, A., GENTILE, F., Padova, M. D., Rubiu, O., & Floridi, A. (2000) · PubMed · Cited by 72
Wartenberg, M., Richter, M., Datchev, A., Guenther, S., Milosevic, N., Bekhite, M. M., Figulla, H., Aran, J. M., Pétriz, J., & Sauer, H. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22422 · Cited by 72
GAPDH and Intermediary Metabolism
Seidler, N. W. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-4716-6_2 · Cited by 71
Chen, G., Tang, C., Shi, X., Lin, C., Fatima, S., Pan, X., Yang, D., Zhang, G., Lü, A., Lin, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4376 · Cited by 71
Papagerakis, S. M., Bellile, E. L., Peterson, L. A., Pliakas, M. C., Balaskas, K., Selman, S., Hanauer, D. A., Taylor, J. M. G., Duffy, S. A., & Wolf, G. T. (2014) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-14-0002 · Cited by 71
Untuning the tumor metabolic machine: Targeting cancer metabolism: a bedside lesson
Birsoy, K., Sabatini, D. M., & Possemato, R. (2012) · Nature Medicine · doi:10.1038/nm.2870 · Cited by 69
Pacheco, A. G., Grinsztejn, B. G. J., da Fonseca, M. D. J. M., Moreira, R. I., Veloso, V. G., Friedman, R. K., Santini-Oliveira, M., Cardoso, S. W., Falcão, M., Mill, J. G., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117461 · Cited by 67
Filipp, F. V. (2013) · Journal of Carcinogenesis · doi:10.4103/1477-3163.115423 · Cited by 67
Liao, S., Zhao, X., Han, Y., Zhang, J., Wang, L., Xia, L., Zhao, K., Zheng, Y., Guo, M., & Chen, G. (2009) · PROTEOMICS · doi:10.1002/pmic.200800922 · Cited by 64
Systemic Delivery of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer
Chapiro, J., Sur, S., Savic, L. J., Ganapathy‐Kanniappan, S., Reyes, J., Durán, R., Chettiar, S. T., Moats, C. R., Lin, M., Luo, W., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1271 · Cited by 63
Ganapathy‐Kanniappan, S., Geschwind, J. F., Kunjithapatham, R., Buijs, M., Syed, L. H., Rao, P. P., Ota, S., Kwak, B. K., Loffroy, R., & Vali, M. (2010) · PubMed · Cited by 62
Targeting the mTOR Pathway in Leukemia
Dinner, S. N., & Platanias, L. C. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25559 · Cited by 60
Zhang, D., Hedlund, E., Lim, S., Chen, F., Zhang, Y., Sun, B., & Cao, Y. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016220108 · Cited by 59
Essential Role for Oxidative Phosphorylation in Cancer Progression
Maiuri, M. C., & Kroemer, G. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2014.12.013 · Cited by 56
Yeh, C., Wang, J., Chung, F., Lee, S., Huang, M., Kuo, C.-W., Yang, M.-J., & Lin, S. (2008) · Oncology Reports · doi:10.3892/or.19.1.81 · Cited by 54
Tao, L., Wei, L., Liu, Y., Ding, Y., Liu, X., Zhang, X., Wang, X., Yao, Y., Lu, J., Wang, Q., et al. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.11.001 · Cited by 54
Amadori, D., Frassineti, G. L., Matteis, A. D., Mustacchi, G., Santoro, A., Cariello, S., Ferrari, M., Nascimben, O., Nanni, O., Lombardi, A., et al. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006063412726 · Cited by 52
Li, C., Liu, V. W. S., Chan, D. W., Yao, K. M., & Ngan, H. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e3182322834 · Cited by 52
Acute toxicity and cardio-respiratory effects of 2-deoxy-D-glucose: a promising radio sensitiser.
Vijayaraghavan, R., Kumar, D., Dube, S. N., Singh, R., Pandey, K., Bag, B. C., Kaushik, M. P., Sekhar, K. R., Dwarakanath, B. S. R., & Ravindranath, T. (2006) · PubMed · Cited by 52
Ganapathy‐Kanniappan, S., Kunjithapatham, R., Torbenson, M. S., Rao, P. P., Carson, K. A., Buijs, M., Vali, M., & Geschwind, J.-F. H. (2012) · Radiology · doi:10.1148/radiol.11111569 · Cited by 51
Vali, M., Liapi, E. A., Kowalski, J., Hong, K. K., Khwaja, A. A., Torbenson, M. S., Georgiades, C. S., & Geschwind, J.-F. H. (2007) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2006.10.019 · Cited by 48
Dai, Y., Xiong, X., Huang, G., Liu, J., Sheng, S., Wang, H., & Qin, W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092962 · Cited by 47
Evolution of GAPDH as a druggable target of tumor glycolysis?
Ganapathy‐Kanniappan, S. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1449834 · Cited by 44
Falcone, R., Roberto, M., D’Antonio, C., Romiti, A., Milano, A., Onesti, C. E., Marchetti, P., & Fais, S. (2016) · Digestive and Liver Disease · doi:10.1016/j.dld.2016.08.126 · Cited by 43
WANG, Z., ZHANG, L., ZHANG, D., et al. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2945 · Cited by 41
Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells
Xie, C., Li, Y., Li, L.-L., Fan, X.-X., Wang, Y.-W., Wei, C.-L., Liu, L., Leung, E. L.-H., & Yao, X.-J. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00823 · Cited by 40
Kennedy, C. R., Tilkens, S. B., Guan, H., Garner, J. A., Or, P. M. Y., & Chan, A. M.-L. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.03.020 · Cited by 39
Dwarakanath, B. S. R., Prasanna, V., Venkataramana, N. K., & Santhosh, V. (2009) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.55141 · Cited by 39
Vali, M., Vossen, J. A., Buijs, M., Engles, J. M., Liapi, E. A., Ventura, V. P., Khwaja, A. A., Acha-Ngwodo, O., Ganapathy‐Kanniappan, S., Syed, L. H., et al. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.141093 · Cited by 38
Mediani, L., Gibellini, F., Bertacchini, J., Frasson, C., Bosco, R., Accordi, B., Basso, G., Bonora, M., Calabrò, M. L., Mattiolo, A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6315 · Cited by 35
Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer
Gadducci, A., Brunetti, I. M., Muttini, M. P., FANUCCHI, A., Dargenio, F., Giannessi, P. G., & Conte, P. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)00231-s · Cited by 34
Cao, X., Jia, G., Zhang, T., Yang, M. H., Wang, B., Wassenaar, P. A., Cheng, H., Knopp, M. V., & Sun, D. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0688-8 · Cited by 32
Lena, M. D., Lorusso, V., Bottalico, C., Brandi, M., Mitrio, A. D., Catino, A., Guida, M., Latorre, A. C., Leone, B. A., Vallejo, C. T., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.10.3208 · Cited by 32
DCA promotes progression of neuroblastoma tumors in nude mice.
Feuerecker, B., Seidl, C., Pirsig, S., Bruchelt, G., & Senekowitsch–Schmidtke, R. (2015) · Europe PMC (PubMed Central) · Cited by 28
Ota, S., Geschwind, J.-F. H., Buijs, M., Wijlemans, J. W., Kwak, B. K., & Ganapathy‐Kanniappan, S. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0273-x · Cited by 28
Savic, L. J., Chapiro, J., Duwe, G., & Geschwind, J.-F. (2015) · Hepatic Oncology · doi:10.2217/hep.15.36 · Cited by 28
Monteleone, F., Rosa, R., Vitale, M., DˈAmbrosio, C., Succoio, M., Formisano, L., Nappi, L., Romano, M. F., Scaloni, A., Tortora, G., et al. (2012) · PROTEOMICS · doi:10.1002/pmic.201200303 · Cited by 27
Kalia, V. K., Prabhakara, S., & Narayanan, V. (2009) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.55145 · Cited by 25
Chen, C., Lee, C., Lin, Y., Kao, L., & Lin, H. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1329 · Cited by 25
Muley, P., Olinger, A., & Tummala, H. (2015) · Nutrition and Cancer · doi:10.1080/01635581.2015.1002626 · Cited by 23
The regulatory properties of yeast pyruvate kinase. Effect of pH
Kinderlerer, J., Ainsworth, S., Morris, C. N., et al. (1986) · Biochemical Journal · doi:10.1042/bj2340699 · Cited by 17
Buijs, M., Wijlemans, J. W., Kwak, B. K., Ota, S., & Geschwind, J.-F. H. (2013) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2013.01.013 · Cited by 15
Candidate cancer drug suspected after death of three patients at an alternative medicine clinic
Feldwisch‐Drentrup, H. (2016) · Science · doi:10.1126/science.aah7192 · Cited by 15
Tomoda, A. (2011) · Oncology Reports · doi:10.3892/or.2011.1531 · Cited by 12
Cited by
Altered metabolism in cancer: insights into energy pathways and therapeutic targets
Tufail, M., Jiang, C.-H., & Li, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02119-3 · Cited by 534
EMT Factors and Metabolic Pathways in Cancer
Georgakopoulos-Soares, I., Chartoumpekis, D. V., Kyriazopoulou, V., & Zaravinos, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00499 · Cited by 349
Crosstalk between glucose metabolism, lactate production and immune response modulation
Ye, L., Jiang, Y., & Zhang, M. (2022) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2022.11.001 · Cited by 306
Signaling pathways in cancer metabolism: mechanisms and therapeutic targets
You, M., Xie, Z., Zhang, N., Zhang, Y., Xiao, D., Liu, S., Zhuang, W., Li, L., & Tao, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01442-3 · Cited by 292
Emerging therapies in cancer metabolism
Xiao, Y., Yu, T.-J., Xu, Y., Ding, R., Wang, Y.-P., Jiang, Y.-Z., & Shao, Z.-M. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.07.006 · Cited by 256
Metadata
- Authors
- Abdel-Wahab, A. F., Mahmoud, W., & Al-Harizy, R. M.
- Venue
- Pharmacological Research
- Publisher
- Elsevier BV
- Published
- 2019-12
- Volume
- 150
- Pages
- 104511
- ISSN
- 1043-6618 (ISSN-L)
- OpenAlex
- W2985781565
- Cited by
- 591
- References
- 261
- FWCI
- 14.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.